Edition:
United States

BioLine RX Ltd (BLRX.TA)

BLRX.TA on Tel Aviv Stock Exchange

335.00ILa
10:23am EDT
Change (% chg)

1.10 (+0.33%)
Prev Close
333.90
Open
332.20
Day's High
345.10
Day's Low
327.10
Volume
210,462
Avg. Vol
137,435
52-wk High
500.00
52-wk Low
286.60

BLRX.TA

Chart for BLRX.TA

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)
No analyst recommendations are available for BLRX.TA.

Overall

Beta: -0.35
Market Cap(Mil.): ₪320.33
Shares Outstanding(Mil.): 95.62
Dividend: --
Yield (%): --

Financials

  BLRX.TA Industry Sector
P/E (TTM): -- 211.50 15.59
EPS (TTM): -1.01 -- --
ROI: -37.97 -8.04 -8.43
ROE: -38.34 -9.41 -8.00

BRIEF-Biolinerx announces additional investment from BVF Partners L.P.

* BiolineRx announces additional investment from BVF partners L.P.

7:45am EDT

BVF raises stake in biopharma firm BioLineRx to 24.9 pct

* Israeli biopharmaceutical firm BioLineRx said on Wednesday that BVF Partners, its largest shareholder, agreed to invest an additional $9.6 million in BioLineRx, raising its holding to 24.9 percent from 18.3 percent.

7:00am EDT

BRIEF-BiolineRx reports regulatory submissions of 3 Phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

* BiolineRx reports regulatory submissions of three phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors

Jun 01 2017

BRIEF-BioLine Rx reports Q1 loss per share $0.06

* BioLine Rx Ltd qtrly loss per share $0.06 Source text for Eikon: Further company coverage:

May 25 2017

BRIEF-Biolinerx announces regulatory submission for phase 1B trial of BL-8040

* Biolinerx announces regulatory submission for phase 1B trial of BL-8040 in combination with atezolizumab in AML

May 22 2017

BRIEF-BioLineRx to begin late-stage study testing stem cell treatment

* Biolinerx to initiate phase 3 study with bl-8040 as novel stem cell mobilization treatment following successful meeting with fda

May 03 2017

BRIEF-BVF Inc reports 18.3 pct passive stake in Bioline RX Ltd

* BVF Inc reports 18.3 percent passive stake in Bioline RX Ltd as on March 31, 2017 Source text:(http://bit.ly/2p0kRot) Further company coverage:

Apr 10 2017

BRIEF-BioLineRx prices $25 mln underwritten public offering

* BioLine rx ltd - priced underwritten public offering of about 29.4 million ADSs at public offering price of $0.85 per ads Source text for Eikon: Further company coverage:

Mar 31 2017

BRIEF-BioLine RX announces underwritten public offering of its american depositary shares

* BioLine RX announces underwritten public offering of its american depositary shares

Mar 30 2017

BRIEF-BiolineRX announces acquisition of Agalimmune Ltd

* Biolinerx announces acquisition of Agalimmune Ltd to accelerate expansion of immuno-oncology pipeline

Mar 23 2017

Earnings vs. Estimates